40 results found.

Malaria Clinical Trial using sulfadoxine/pyrimethamine; Chloroquine

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting N/A or older.
- A Randomized, Controlled Clinical Trial of Chloroquine as Chemoprophylaxis Versus Intermittent Preventive Therapy to Prevent Malaria in Pregnancy in Malawi.
sulfadoxine/pyrimethamine; Chloroquine

Malaria Clinical Trial using PfSPZ

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 35 years.
- Assessment of Safety and Immunogenicity of Intravenous Immunization With Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults.
PfSPZ

Plasmodium Falciparum Malaria Clinical Trial using FMP2.1/AS01B

University of Oxford - Recruiting 18 years to 45 years.
- A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria.
FMP2.1/AS01B

Plasmodium Vivax Infection Clinical Trial using Artemether-lumefantrine combination; Primaquine; Chloroquine

Centers for Disease Control and Prevention - Recruiting 1 year or older.
- Ethiopia Antimalarial in Vivo Efficacy Study 2012: Evaluating the Efficacy of Artemether-lumefantrine Alone Compared to Artemether-lumefantrine Plus Primaquine and Chloroquine Alone Compared to Chloroquine Plus Primaquine for Plasmodium Vivax Infection.
Artemether-lumefantrine combination; Primaquine; Chloroquine

Malaria Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A to 45 years.
- Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali.

Iron Deficiency Clinical Trial using Ferrous sulfate

Columbia University - Recruiting 18 years to 50 years.
- Malaria and Iron Intervention Safety: Absorption and NTBI.
Ferrous sulfate

Malaria, Prevention and Control, Acquired Immunity, or Parasitemi Clinical Trial using PfSPZ

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 45 years.
- VRC 314: A Phase 1, Open-Label, Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Durability of Protection Following Intravenous and Intramuscular Administration of PFSPZ Vaccine in Malaria-Naive Adults.
PfSPZ

Malaria Clinical Trial using Oral Activated Charcoal

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 10 years.
- Effect of Oral Activated Charcoal on Parasite Clearance Rates in Response to Intravenous Artesunate in Malian Children With Uncomplicated Plasmodium Falciparum Malaria.
Oral Activated Charcoal

Malaria Clinical Trial using Pfs25-EPA; Euvax/Hepatitis B vaccine; Menatra/Meningococcal Groups A, C, Y, W-135 vaccine; Alhydrogel

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 45 years.
- Double Blind Dose-Escalating Randomized Controlled Phase 1 Study in Malaria Exposed Adults of the Safety and Immunogenicity of Pfs25-EPA/ Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum in Bancoumana, Mali.
Pfs25-EPA; Euvax/Hepatitis B vaccine; Menatra/Meningococcal Groups A, C, Y, W-135 vaccine; Alhydrogel

Chagas Disease, Malaria, Parasitic Disease, or Trypanosomiasis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 1 year to 85 years.
- Evaluation, Treatment, and Monitoring of Patients With Known or Suspected Parasitic Infection.

Malaria Clinical Trial using Ottawa Malaria Decision Aid

Ottawa Hospital Research Institute - Recruiting 18 years or older.
- Incorporation of the 'Ottawa Malaria Decision Aid' Into the Pre-travel Consultation Process: Assessment of Travelers' Knowledge, Decisional Conflict, Preparation for Decision-making and Medication Adherence Compared to Standard Care.
Ottawa Malaria Decision Aid

Cure Rate Clinical Trial using KAE609

Novartis - Recruiting 20 years to 60 years.
- An Open Label, Single Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum Malaria Mono-infection.
KAE609

Malaria Clinical Trial using Artesunate-amodiaquine; Dihydroartemisinin-piperaquine; Artemether-lumefantrine

Epicentre - Recruiting 6 Months to 59 Months.
- Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6 to 59 Months in Maradi, Niger 2012-13.
Artesunate-amodiaquine; Dihydroartemisinin-piperaquine; Artemether-lumefantrine

Seizure, Epilepsy, or Cerebral Malaria Clinical Trial using Oral Levetiracetam; Standard AED

University of Rochester - Recruiting 24 Months to 83 Months.
- .
Oral Levetiracetam; Standard AED

Malaria Clinical Trial using KAF156 400 mg; KAF156 800 mg

Novartis - Recruiting 20 years to 60 years.
- A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection.
KAF156 400 mg; KAF156 800 mg

Acute Uncomplicated Falciparum Malaria Clinical Trial using COA566; Artemether-lumefantrine dispersible tablet

Novartis - Recruiting N/A or older.
- An Open-label, Single-arm Study to Evaluate the Efficacy, Safety and PK of Artemether-lumefantrine Dispersible Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants <5 kg Body Weight.
COA566; Artemether-lumefantrine dispersible tablet

Plasmodium Falciparum Malaria Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 65 years.
- Artemisinin-resistant Plasmodium Falciparum Malaria in Cambodia.

Malaria Clinical Trial using Blood sampling; Assessment of body temperature

GlaxoSmithKline - Recruiting 6 Months or older.
- Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa.
Blood sampling; Assessment of body temperature

Safety of Candidate Malaria Vaccine Clinical Trial using Group A1 : 50æg AMA1-DiCo + Alhydrogel; Group A2 : 50 æg AMA1-DiCo+ GLA-SE; Group B2 : Placebo

Institut National de la Sant‚ Et de la Recherche M‚dicale, France - Recruiting 20 years to 45 years.
- Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel r as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults:a Staggered Phase Ia/Ib, Randomised, Double-blind, Multi-Centre Trial.
Group A1 : 50æg AMA1-DiCo + Alhydrogel; Group A2 : 50 æg AMA1-DiCo+ GLA-SE; Group B2 : Placebo

Plasmodium Falciparum Malaria Clinical Trial using Eurartesim dispersible oral tablet; eurartesim film coated tablet

sigma-tau i.f.r. S.p.A. - Recruiting 6 Months to 12 Months.
- A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamics and Safety Study of a New Paediatric Eurartesim Dispersible Formulation and Crushed Film Coated Eurartesim Tablet, in Infant Patients With P. Falciparum Malaria.
Eurartesim dispersible oral tablet; eurartesim film coated tablet

Plasmodium Falciparum Infection Clinical Trial using Artemether-lumefantrine 3 days; Artemether-lumefantrine 5 days

University of Oxford - Recruiting 6 years or older.
- An Open-label Randomized Controlled Trial to Evaluate the Effectiveness and Safety of a 3 Day Versus 5 Day Course of Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in Myanmar.
Artemether-lumefantrine 3 days; Artemether-lumefantrine 5 days

Iron Deficiency Anemia, or Malaria Clinical Trial using Iron Supplement

University of North Carolina, Chapel Hill - Recruiting 18 years to 70 years.
- Impact of Host Iron Status and Iron Supplement Use on Growth and Viability of the Erythrocytic Stage of Plasmodium Falciparum.
Iron Supplement

Diarrhea, or Malaria Clinical Trial using Classic Intervention; Minimum Intervention

Georgetown University - Recruiting N/A to 5 years.
- Health Impact Evaluation of the 'Community-Based Environmental Health Promotion Programme' in Rwanda.
Classic Intervention; Minimum Intervention

Malaria, Pneumonia, or Diarrhoea Clinical Trial using Technology supported supervision; Community supported supervision; Integrated community case management

Malaria Consortium Africa - Recruiting N/A or older.
- Integrated Community Case Management of Common Childhood Diseases: Mozambique and Uganda.
Technology supported supervision; Community supported supervision; Integrated community case management

Vivax Malaria Clinical Trial using Chloroquine; Chloroquine/Primaquine

University of Oxford - Recruiting 6 Months or older.
- Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan.
Chloroquine; Chloroquine/Primaquine

Burkitt Lymphoma, Malaria, or Epstein-Barr Virus Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A to 15 years.
- Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM).

Iron Deficiency, Malaria, Nutrition, or Global Health Clinical Trial using Ferrous sulfate syrup; iron stable isotope 57Fe; iron stable isotope 58Fe

University of Minnesota - Clinical and Translational Science Institute - Recruiting 6 Months to 36 Months.
- Acute vs. Delayed Iron: Effect on Red Cell Iron Incorporation in Severe Malaria.
Ferrous sulfate syrup; iron stable isotope 57Fe; iron stable isotope 58Fe

Malaria Clinical Trial using Artesunate-Amodiaquine; Dihydroartemisinine-Piperaquine; Artemether-lumefantrine combination

University of Yaounde 1 - Recruiting 6 Months to 120 Months.
- Phase III Study to Study the Clinical Response to ACT Fixed Dose Combination in 42 Days in Uncomplicated Malaria in Cameroon.
Artesunate-Amodiaquine; Dihydroartemisinine-Piperaquine; Artemether-lumefantrine combination

Malaria Clinical Trial using OZ439

Medicines for Malaria Venture - Recruiting 18 years to 60 years.
- The Extended Observation Over a Period of 28 Days of the Effects of Single Doses of OZ439 on the Recrudescence of Plasmodium Falciparum Malaria - a PhIIa, Open Label Study in Adult Patients.
OZ439

Acute Uncomplicated Malaria With PVivax Infection Clinical Trial using Artesunate; Chloroquine

Mahidol University - Recruiting 18 years to 65 years.
- An Open Label Randomized Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand.
Artesunate; Chloroquine

Diarrhoea, Malaria, Pneumonia, Breastfeeding, or Under-nutrition Clinical Trial using Local radio campaign to reduce under-five child mortality

London School of Hygiene and Tropical Medicine - Recruiting N/A to 5 years.
- Can Mass Media Campaigns Reduce Child Mortality.
Local radio campaign to reduce under-five child mortality

Malaria, or Plasmodium Falciparum Clinical Trial using PfSPZ Challenge; Normal Saline (NS)

Sanaria Inc. - Recruiting 18 years to 35 years.
- Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis.
PfSPZ Challenge; Normal Saline (NS)

Fever, or Malaria Clinical Trial using Field microscopy and Paracheck Pfr

Makerere University - Recruiting 3 Months or older.
- Parasite-based Diagnosis for Malaria in Uganda: Feasibility and Cost-Effectiveness.
Field microscopy and Paracheck Pfr

Malaria Clinical Trial using MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP; Verorab vaccine

African Malaria Network Trust - Recruiting 12 Months to 48 Months.
- Phase IIb Immunogenicity, Efficacy and Safety Study of P. Falciparum Vaccine Candidate, MSP3-LSP Adjuvanted in Aluminium Hydroxide Versus Verorab Control in Healthy Children Aged 12-48 Months in Mali..
MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP; Verorab vaccine